Anti-CD254/RANKL/TNFSF11 Polyclonal Antibody (HT439014)

Datasheet Share product Copy info

Price(USD): $

Spec:

20ug
50ug
100ug

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.

HT439014

Description

Anti-CD254/RANKL/TNFSF11 Polyclonal Antibody (HT439014) is a rabbit polyclonal antibody detecting TNFSF11 in ELISA, IHC, WB. Suitable for Human.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

Species reactivity

Human

Applications

ELISA, IHC, WB

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human CD254/RANKL/TNFSF11 (Tyr69-Asp317).

Target

ODF, TNF-related activation-induced cytokine, Osteoclast differentiation factor, TNFSF11, TRANCE, Osteoprotegerin ligand, RANKL, Tumor necrosis factor ligand superfamily member 11, Receptor activator of nuclear factor kappa-B ligand, CD254, OPGL

Purification

Purified by antigen affinity column.

Accession

O14788

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Tumor necrosis factor ligand superfamily member 11 (CD254/RANKL) is a ~35 kDa protein. Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. CD254 is the therapeutic target of denosumab (Prolia).

1. Luan, X. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 189, 245-52. PMID: 22664871

Note

For research use only.

Images

Western blot

Western blot analysis was performed using anti-RANKL polyclonal antibody at RANKL on various samples.
Lane 1: HUVEC cell lysate
Lane 2: RAW264.7 cell lysate
Lane 3: Raji cell lysate
Lane 4: Mouse spleen lysate
Lane 5: Mouse liver lysate